Association between post-procedural hyperoxia and poor functional outcome after mechanical thrombectomy for ischemic stroke: an observational study

Héctor Vargas López1*, Miguel Fernández Vivas1, Rafael Núñez Ruíz1, José Ros Martínez1, Blanca García-Villalba Navaridas2, Manuel García Villa1, Cristina Llamas Lázaro1, Rubén Jara Rubio1, Ana Morales Ortiz3, Laura Albert Lacal3 and Antonio Moreno Diéguez2

Abstract

Background: The actual effects of oxygen therapy on patients who have suffered a stroke are still unknown, and its recommendation as a routine measure in emergency services remains controversial. The aim of this study is to determine the effect of hyperoxia in functional recovery in patients with ischemic stroke who underwent intra-arterial mechanical thrombectomy (IAMT).

Methods: A prospective observational cohort study that included all adult patients consecutively admitted to the intensive care unit (ICU) due to an ischemic stroke in the anterior cerebral circulation and following an IAMT intervention, between 2010 and 2015. All patients were intubated and connected to mechanical ventilation for the intra-arterial therapy, receiving supplementary oxygen to achieve saturations above 94%. Two groups were established regarding oxygen partial pressure (paO2) reached. It was based on a single ICU admission blood gas analysis. The hyperoxia group was defined as paO2 > 120 mmHg. We measured functional recovery in each of the groups according to the modified Rankin scale after 90 days.

Results: For the analysis, a total of 333 patients were included. High levels of paO2 were mostly related to higher scores in modified Rankin scale (mRS) after 90 days. There were 60.6% cases with mRS ≥ 4 and 70.6% with mRS ≥ 3 in the hyperoxia group, compared to 43.0% and 56.1% in the paO2 ≤ 120 group, \(p < 0.01\), respectively. Mortality was higher in the hyperoxia group, 28.6% vs 18.7%, \(p = 0.04\). After regression adjustment by confounding factors, poor functional outcome was still significantly higher in the hyperoxia group, for both mRS ≥ 4 and mRS ≥ 3: OR 2.27, IC 95%, 1.22–4.23, \(p = 0.01\) and OR 2.07, IC 95%, 1.05–4.029, \(p = 0.04\), respectively. Both the National Institute of Health Stroke Scale Score (NIHSS) values at 24 h after the IAMT and the days of ICU stay were significantly higher in the hyperoxia group.

Conclusions: In patients with ischemic stroke in the anterior cerebral circulation treated with IAMT, we found an association between admission PaO2 > 120 mmHg and worse functional outcome 90 days after ischemic stroke, but this association needs further confirmation by other studies.

Keywords: Hyperoxia, Stroke, Mortality, Ischemic, Oxygen, Cerebral blood flow

*Correspondence: hvlf12v@gmail.com
1 Department of Intensive Care, Virgen de la Arrixaca, Clinical University Hospital, Murcia, Spain
2 Full list of author information is available at the end of the article

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Background
According to the World Health Organization’s data analysis, cerebrovascular diseases are the third leading cause of death in the Western world and the first cause of physical disability in adults. Over 15 million people per year, the equivalent of one in 400 people, suffer from a stroke in the world [1].

In Spain, the overall rate of ischemic stroke, excluding transient ischemic attacks, is 140 per every 100,000 inhabitants per year [2].

The brain is an extremely sensitive organ to hypoxia. Insufficient oxygen supply leads to a critical cerebral metabolic situation. Hypoxia during stroke has been related to a higher death risk [3], since it can worsen the lesions resulting from cerebral ischemia in this kind of patients, especially in those patients whose cerebral flow autoregulation mechanism has been affected by ischemia.

Until a few years ago, the only reperfusion therapy approved for the treatment of patients with stroke was intravenous thrombolysis by tissue plasminogen activators, such as alteplase, within the first 4.5 h after the stroke.

Recently, and particularly after the publication of the results obtained in the “MrClean” multicenter trial [4], it has been proved that endovascular recanalization therapies by means of mechanical devices are faster and have a higher success rate in vessel revascularization, especially in strokes affecting large proximal arteries [5, 6], and they also allow widening the therapeutic window up to 8 h in the case of anterior territory strokes [7].

Although oxygen therapy is frequently used to minimize the effects of hypoxia in patients who have suffered a stroke, its role is still controversial and it is not without problems [8]. Oxygen therapy can worsen the ventilation–perfusion ratio and cause atelectasis or cerebral, coronary and systemic vasoconstriction.

Oxidative stress arising from the production of reactive oxygen species has been proposed as a basic cause of brain damage in cerebrovascular accidents particularly during the reperfusion subsequent to revascularization of the affected territory [9, 10].

In the medical literature, there is no consensus regarding the real effects of oxygen therapy in patients who have suffered a stroke, or regarding its recommendation as a routine measure in emergency services. There are studies focused on its possible side effects [11], while others defend its probable neuroprotective role in allowing the widening of the narrow therapeutic window until thrombolysis/thrombectomy is performed [12].

This study evaluates the role of oxygen supplementation in patients with ischemic stroke.

Methods
Aims of the study
The main goal of this study was to determine the effect of hyperoxia in functional recovery in patients with ischemic stroke who underwent intra-arterial mechanical thrombectomy (IAMT).

Design and setting
This was a prospective observational cohort study, with follow-up without repeated measures.

The study was approved by the Hospital Ethics Committee, and since there was no interference with patients’ management, signed informed consent was waived.

The study population included all patients consecutively admitted to the intensive care unit (ICU) of the Virgen de la Arrixaca Clinical University Hospital, Murcia (Spain), because of an ischemic stroke in the anterior cerebral circulation and following an IAMT, between April 2010 and December 2015.

The relationship between the oxygenation of the patients and the obtaining of a poor functional outcome was evaluated 90 days after the intervention.

The baseline neurological status of the patient, modified Rankin scale (mRS), National Institute of Health Stroke Scale Score (NIHSS) and Glasgow Coma Scale (GCS) were registered at the time of arrival at hospital. An urgent blood test, electrocardiogram and neuroimaging protocol with multimodal CT (unenhanced CT, perfusion CT and CT angiography) were performed. \( O_2 \) was administered to maintain arterial saturation over 94%.

After diagnosis of ischemic stroke and location of the responsible vessel occlusion using imaging techniques, a fibrinolysis with alteplase (rtPA) was performed on patients who were within a period of < 4.5 h since the onset of symptoms and who met the selection criteria (Additional file 1). In the cases in which these criteria were not met, or those in which the patient’s evolution was not favorable, intra-arterial mechanical thrombectomy was considered by the Neuroradiology Service. It was performed on patients who had an obstruction of the intracranial or extracranial internal carotid artery or of the trunk of the middle cerebral artery, with a mismatch of at least 30% by CT perfusion, when no more than 8 h had elapsed from the onset of symptoms, as long as there were no contraindications (Additional file 1).

All patients for the intra-arterial therapy were intubated and connected to mechanical ventilation. They received supplementary oxygen to achieve saturations above 94%, according to the criteria of the anesthesiologists. After the intervention, they were admitted in ICU. FiO\(_2\) and PEEP levels delivered at ICU admission: 0.5 (0.4–0.6) and 6 (5–7), respectively (variables expressed as median and interquartile range). Some patients
were extubated prior to ICU admission. These patients received supplementary oxygen: FO2 0.5 (0.5–0.8), variable expressed as median and interquartile range.

Once in the unit, arterial oxygen partial pressure (paO₂) was measured by means of a control blood gas analysis, according to usual clinical practice. Two groups were formed. They were based on the paO₂ levels reached of a single ICU admission blood gas analysis. As a cutoff, a paO₂ of 120 mmHg was established, according to the literature review [13]. The hyperoxia group was defined as paO₂ > 120 mmHg.

We evaluated the degree of functional recovery in each of the groups after 90 days (primary endpoint), objectively measured according to the mRS through a structured interview. This scale has 7 scores, which range from 0 (no symptoms at all) to 6 (dead).

The length of the patient’s stay in the ICU and the NIHSS were included as secondary endpoints after the procedure for each study group.

They stayed in this unit for at least 24 h, depending on their progress. Then, they were admitted into the intermediate care unit specially prepared for that purpose.

Statistical analysis
A univariate analysis was performed in order to study the relationship between hyperoxia with baseline characteristics and the variables established as primary and secondary endpoints. We used the Chi-squared test for qualitative variables and the Mann–Whitney U test for quantitative variables.

We performed a statistical adjustment by logistic regression to study the relationship between hyperoxia and a poor functional outcome. The variables that met criteria of confounding factors were introduced in the model. The model included variables that were significant at p value of less than 0.25 in univariate analysis. Finally, we obtained the most parsimonious model that did not modify the odds ratio in more than 10%, according to the parsimony principle: sex, age, APACHE score, preprocedure NIHSS, wearable tissue area (mismatch), reperfusion degree achieved and persistence of orotracheal intubation at ICU admission (Additional file 2).

After adjustment, poor functional outcome remained significantly higher in the hyperoxia group for both mRS ≥ 4 and mRS ≥ 3: OR 2.27, IC 95%, 1.22–4.23, p = 0.01 and OR 2.07, IC 95%, 1.05–4.029, p = 0.04, respectively (Table 3). Thus, hyperoxia is an available due to incidents in the pre-analytic phase at ICU admission, so a total of 333 patients were finally included in the study (Fig. 1).

The score distribution on the modified Rankin scale 90 days after IAMT between the two groups was clearly unequal. Thus, 60.6% of cases with mRS ≥ 4 and 70.6% with mRS ≥ 3 were observed in the hyperoxia group, compared to 43.0% and 56.1% in the paO₂ ≤ 120 group, OR 2.03 (CI 95%, 1.29–3.21, p < 0.01) and 2.03 (CI 95%, 1.29–3.21, p < 0.01), respectively. Thus, low levels of paO₂ were mostly linked with lower mRS scores (Fig. 2).

Significant differences regarding the baseline situation of patients were observed (Table 1).

Therefore, it was adjusted by logistic regression including the confounding variables identified by a previous univariate analysis (Table 2). Finally, this model was simplified, including only those variables that involved a modification of the OR of the hyperoxia variable greater than 10%, according to the parsimony principle: sex, age, APACHE score, preprocedure NIHSS, wearable tissue area (mismatch), reperfusion degree achieved and persistence of orotracheal intubation at ICU admission (Additional file 2).

After adjustment, poor functional outcome remained significantly higher in the hyperoxia group for both mRS ≥ 4 and mRS ≥ 3: OR 2.27, IC 95%, 1.22–4.23, p = 0.01 and OR 2.07, IC 95%, 1.05–4.029, p = 0.04, respectively (Table 3). Thus, hyperoxia is an
independent factor of poor functional outcome, being twice as frequent among patients with \( mRS \geq 4 \) or \( mRS \geq 3 \).

For \( mRS \geq 4 \) outcome, the model obtained showed a sensitivity of 74.6% and a specificity of 71.3%. The discriminative capacity of the model was evaluated through the construction of a ROC curve. An area under the curve of 0.81 was obtained, concluding that in 81% of the cases we will be able to predict the obtaining of a good/poor functional result based on the \( \text{paO}_2 \) values (Fig. 3).

On the other hand, both the NIHSS values at 24 h after the IAMT and the days of ICU stay were significantly higher in the hyperoxia group (Table 3).

A subgroup analysis was also performed according to the stroke lesion location (Table 4): In the subgroup analysis, there were only statistically significant differences for the M1 group. The confounding variables were identified (Additional file 2), and a logistic regression adjusted to these variables was performed. After adjustment, poor functional outcome remained significantly higher in the hyperoxia group for both \( mRS \geq 4 \) and \( mRS \geq 3 \): OR 2.81, IC 95%, 1.12–7.02, \( p = 0.03 \) and OR 3.56, IC 95%, 1.29–9.84, \( p = 0.01 \), respectively (Table 5).

Discussion

There is a close association between hypoxia, neurotoxicity and mortality after a stroke; however, there is poor evidence regarding the possible benefit of oxygen supplementation in non-hypoxemic patients.

Among the few published studies, there is that of Ronning Om et al. [15], a quasi-randomized trial that included a total of 550 patients with ischemic stroke. They randomized two groups comparing oxygen treatment via nasal cannula at 3 L/min during 24 h from the onset of symptomatology, with no routine oxygen. They concluded that there was a lower overall mortality rate per year, and a lower degree of disability at 7 months in the untreated group, although these differences were not significant.

However, Chiu et al. [16] concluded that there was lower mortality (1 vs 6, \( p = 0.048 \)) and a lower incidence of adverse events, specifically pneumonia (1 vs 6, \( p = 0.048 \)), in patients treated with high flow oxygen via mask at 40% compared to administration in nasal cannula at 2 L/min., only for subgroups with complete occlusion of middle cerebral artery.

This study was followed by a larger trial with a similar design, published by Singhal et al. [17], which was terminated early after enrollment of 86 patients, due to an imbalance in deaths favoring control arm (20% vs 8%). These findings are supported by ours, where hyperoxia was associated with a worse functional outcome.

Rincon et al. [18] observed that patients with hyperoxia had higher mortality than those who had normal \( \text{paO}_2 \) levels or even with hypoxia (OR 1.7, 95% CI, 1.3–2.1, \( p < 0.001 \) vs OR 1.3, 95% CI, 1.1–1.7, \( p < 0.010 \), respectively), in a cohort of 2894 ventilated patients who had suffered a stroke.

However, the results were not as conclusive in the recently published “Stroke Oxygen Study” [19]. A multicenter prospective randomized single-blind trial evaluated routine oxygen treatment during the first 72 h from the cerebrovascular event after randomization.
Table 1 Characteristics of patients at ICU admission

| Characteristic                              | pO2 ≤ 120 mmHg N = 214 | pO2 > 120 mmHg N = 119 | Significance level (p value) |
|--------------------------------------------|-------------------------|------------------------|-----------------------------|
| Age in years                               | 71 (60–78)              | 71 (57–77)             | 0.49                        |
| Male sex                                   | 107 (50.0)              | 55 (46.2)              | 0.51                        |
| Body mass index                            | 27 (25–30)              | 26 (24–28)             | 0.02                        |
| History of smoking                         | 66 (30.8)               | 31 (26.1)              | 0.36                        |
| Baseline Rankin                            |                         |                        |                             |
| 0                                          | 151 (70.9)              | 86 (72.3)              | 0.79                        |
| 1                                          | 44 (20.7)               | 19 (16.0)              | 0.30                        |
| ≥ 2                                        | 18 (8.5)                | 14 (11.8)              | 0.33                        |
| Hypertension                               | 150 (70.1)              | 75 (63.0)              | 0.19                        |
| Dyslipidemia                               | 96 (44.9)               | 48 (40.3)              | 0.42                        |
| Diabetes mellitus                          | 61 (28.5)               | 34 (28.6)              | 0.99                        |
| History of COPDa                           | 19 (8.9)                | 7 (5.9)                | 0.33                        |
| History of CRFb                            | 12 (5.6)                | 7 (5.9)                | 0.92                        |
| Atrial fibrillation/flutter                | 88 (41.1)               | 45 (37.8)              | 0.55                        |
| Previous stroke                            | 26 (12.1)               | 12 (10.1)              | 0.57                        |
| Previous antiaggregating therapy           | 64 (29.9)               | 39 (32.8)              | 0.59                        |
| Previous anticoagulation therapy           | 35 (16.4)               | 18 (15.1)              | 0.77                        |
| Preprocedure GCS                           | 14 (13–15)              | 14 (12–15)             | 0.44                        |
| Preprocedure NIHSS                         | 18 (12–21)              | 19 (14–22)             | 0.09                        |
| APACHE                                     | 15 (12–19)              | 16 (12–22)             | 0.23                        |
| Findings in CT scan                        |                         |                        | 0.11                        |
| Without ischemia                           | 80 (38.1)               | 53 (44.5)              | 0.25                        |
| Acute ischemic areasc                      | 103 (49.0)              | 59 (49.6)              | 0.93                        |
| Areas of ancient stroke                    | 27 (12.9)               | 7 (5.9)                | 0.05                        |
| Mismatch                                   | 70 (50–80)              | 70 (50–80)             | 0.43                        |
| Etiology of stroke                         |                         |                        | 0.01                        |
| Cardioembolic                              | 96 (44.9)               | 34 (28.6)              | <0.01                       |
| Atherothrombotic                           | 69 (32.2)               | 48 (40.3)              | 0.14                        |
| Idiopathic                                 | 49 (22.9)               | 37 (31.1)              | 0.10                        |
| Wake-up stroke                             | 25 (11.7)               | 12 (10.1)              | 0.66                        |
| Time (min.) onset of symptoms—IAMT         | 270 (210–367)           | 300 (220–398)          | 0.24                        |
| Type of intervention                       |                         |                        | 0.85                        |
| Thrombectomy                               | 180 (84.1)              | 101 (84.9)             |                             |
| Thrombectomy + stent                       | 34 (15.9)               | 18 (15.1)              |                             |
| Reperfusion degreee                        |                         |                        | 0.18                        |
| Successful reperfusion                     | 201 (93.9)              | 107 (89.9)             |                             |
| Non-successful reperfusion                 | 13 (6.1)                | 12 (10.1)              |                             |
| OTI at admissione                          | 97 (45.3)               | 79 (66.4)              | <0.01                       |
| MAPf                                        | 87 (73–98)              | 90 (77–103)            | 0.22                        |

This table value of quantitative variables expressed as median and interquartile range. Values of qualitative variables expressed as n (%)  

a Chronic obstructive pulmonary disease  
b Creatinine clearance < 60 ml/min/1.73 m²  
c Included signs of acute ischemia and indirect signs of ischemia: hyperdense middle cerebral artery sign, hemispheric sulcus and/or insular cortex effacement, contrast attenuation, ventricular compression  
d Successful reperfusion included TICI 2b and TICI 3. Non-successful reperfusion includes TICI ≤ 2a  
e Patients intubated at ICU admission after IAMT  
f Mean arterial pressure at ICU admission after IAMT
to three groups: continuous oxygen therapy with nasal cannula at 2–3 L/min, oxygen therapy only at night for three nights and breathing room air. No significant differences were found in mortality or in the degree of functional dependence reached after 3 months, both by mRS and by Barthel scale. There were several factors that differed significantly from our selected cohort of patients: Only 82% of their cases corresponded to an ischemic stroke, whether in the anterior or posterior location. In addition, their patients did not receive any endovascular mechanical treatment (probably in relation to the low NIHSS at admission, median of 5) and presented a significant delay until randomization (median of 20:43 h from the onset of symptomatology).

Hyperoxia conditions may change depending on the study considered. In the literature, the cutoff from which we consider that there is hyperoxia is not well defined. Evert de Jonge et al. observed that both increased \( \text{FiO}_2 \) and high or low \( \text{paO}_2 \) during the first 24 h of admission to the ICU proved to be independent factors of mortality, for a sample of more than 36,000 patients. The \( \text{paO}_2 \) interval that was associated with lower mortality was 94–123 mmHg [13]. This maximum value of \( \text{paO}_2 \) agrees with that of the patients who obtained a worse functional result in our series. Therefore, we have considered the value of 120 mmHg as the limit to establish the conditions of hyperoxia.

Hyperoxia conditions may change depending on the study considered. In the literature, the cutoff from which we consider that there is hyperoxia is not well defined. Evert de Jonge et al. observed that both increased \( \text{FiO}_2 \) and high or low \( \text{paO}_2 \) during the first 24 h of admission to the ICU proved to be independent factors of mortality, for a sample of more than 36,000 patients. The \( \text{paO}_2 \) interval that was associated with lower mortality was 94–123 mmHg [13]. This maximum value of \( \text{paO}_2 \) agrees with that of the patients who obtained a worse functional result in our series. Therefore, we have considered the value of 120 mmHg as the limit to establish the conditions of hyperoxia.

The harmful effects of hyperoxia have been known for decades and are attributed mainly to oxidative stress due to an increase in free radicals [10]. In ischemic stroke, and fundamentally after reoxygenation that occurs during the reperfusion phase, free radicals are generated,

Table 2 Confounding variables included in the regression model

| Characteristic                          | mRS < 4 N = 169 | mRS ≥ 4 N = 164 | Significance level (p value) |
|----------------------------------------|-----------------|-----------------|-----------------------------|
| Age in years                           | 67 (55–76)      | 74 (66–79)      | <0.01                       |
| Male sex                               | 84 (49.7)       | 78 (47.6)       | 0.70                        |
| History of smoking                     | 57 (33.7)       | 40 (24.4)       | 0.06                        |
| Baseline Rankin                        |                 |                 | 0.02                        |
| 0                                      | 130 (76.9)      | 107 (65.6)      | 0.02                        |
| 1                                      | 27 (16.0)       | 36 (22.1)       | 0.16                        |
| ≥ 2                                    | 12 (7.1)        | 20 (12.3)       | 0.11                        |
| Hypertension                           | 104 (61.5)      | 121 (73.8)      | 0.02                        |
| Diabetes mellitus                      | 40 (23.7)       | 55 (33.5)       | 0.05                        |
| History of COPD                        | 10 (5.9)        | 16 (9.8)        | 0.19                        |
| History of CRF                         | 7 (4.1)         | 12 (7.3)        | 0.21                        |
| Previous anticoagulation therapy       | 22 (13.0)       | 31 (18.9)       | 0.14                        |
| Preprocedure GCS                       | 15 (14–15)      | 14 (11–15)      | <0.01                       |
| Preprocedure NIHSS                     | 16 (11–20)      | 19 (16–22)      | <0.01                       |
| APACHE                                 | 13 (12–17)      | 18 (14–24)      | <0.01                       |
| Findings in TC                         |                 |                 | 0.12                        |
| Without ischemia                       | 74 (44.3)       | 59 (36.4)       | 0.14                        |
| Acute ischemic areas\(^b\)             | 73 (43.7)       | 89 (54.9)       | 0.04                        |
| Areas of ancient stroke                | 20 (12.0)       | 14 (8.6)        | 0.32                        |
| Mismatch                               | 70 (60–80)      | 60 (40–80)      | <0.01                       |
| Wake-up stroke                         | 14 (8.3)        | 23 (14.0)       | 0.10                        |
| Time (min.) onset of symptoms to IAMT  | 270 (210–360)   | 290 (211–390)   | 0.17                        |
| Reperfusion degree\(^c\)               |                 |                 | <0.01                       |
| Successful reperfusion                 | 164 (97.0)      | 144 (87.8)      |                             |
| Non-successful reperfusion             | 5 (3.0)         | 20 (12.2)       |                             |
| OTI at admission\(^d\)                | 71 (42.0)       | 105 (64.0)      | <0.01                       |

This table value of quantitative variables expressed as median and interquartile range. Values of qualitative variables expressed as n (%)

\(^a\) Creatinine clearance < 60 ml/min/1.73 m²

\(^b\) Included signs of acute ischemia and indirect signs of ischemia: hyperdense middle cerebral artery sign, hemispheric sulcus and/or insular cortex effacement, contrast attenuation, ventricular compression

\(^c\) Successful reperfusion included TICI 2b and TICI 3. Non-successful reperfusion includes TICI ≤ 2a

\(^d\) Patients intubated at ICU admission after IAMT
which favor the development of an inflammatory response that begins at the microvascular level. This causes an increase in oxidative stress and the reactions that occur in the cytosol and organelles, responsible for causing lesions at the endothelial and parenchymal levels [20]. Some authors have proposed that hyperoxia in critically ill patients could interrupt the establishment of compensation mechanisms (mitochondrial, genes related to HIF-1...), paradoxically causing a detrimental effect [21].

In parallel, in the field of cardiology, there are multiple studies that highlight the deleterious effects of oxygen. It is known to cause constriction in different vascular territories, among which are the coronary arteries, in addition to the cerebral, pulmonary and renal arteries. Thus, ventilation with a high fraction of inspired oxygen is associated with reduced cardiac output [22].

It has been shown that normobaric hyperoxia reduces coronary blood flow by 8–29% in both normal subjects and patients with coronary heart disease or chronic heart failure. This causes a decrease in the release and availability of oxygen at the myocardial level [23].

Based on all the available evidence, the European Society of Cardiology proposed that oxygen should not be routinely administered to patients with suspected acute coronary syndrome unless the oxygen saturation was below 90% [24].

According to these findings, studies in healthy subjects have shown that hyperoxia is associated with a decrease in cerebral blood flow [25], which can be reduced by 11–33% [26, 27].

The reasons why oxygen causes constriction at the microvascular level are still not completely clear. Among other mechanisms is the interruption of compensatory mechanisms, such as the inhibition of prostaglandins, favored by the production of ERO [28], the inactivation of nitric oxide (NO) by superoxide anion [29] or the interruption in the release of ATP by red blood cells in situations of hypoxia [30]. Other studies suggest that

---

**Table 3  Study outcomes**

| Score on the mRS at 90 days | \( \text{paO}_2 \leq 120 \text{ mmHg} \ N = 214 \) | \( \text{paO}_2 > 120 \text{ mmHg} \ N = 119 \) | Significance level \((p \text{ value})\) |
|-----------------------------|---------------------------------|---------------------------------|------------------|
| 0–1                         | 70 (32.7)                       | 30 (25.2)                       | 0.15             |
| 0–2                         | 94 (43.9)                       | 35 (29.4)                       | <0.01            |
| 0–3                         | 122 (57.0)                      | 47 (39.5)                       | <0.01            |

**Primary endpoint**

| \( \text{mRS} \geq 4 \text{ at 90 days} \) | \( \text{paO}_2 \leq 120 \text{ mmHg} \ N = 214 \) | \( \text{paO}_2 > 120 \text{ mmHg} \ N = 119 \) | Unadjusted OR value (CI 95%) | Adjusted OR value (CI 95%) |
|----------------------------------------|---------------------------------|---------------------------------|------------------|------------------|
| 92 (43.0)                              | 72 (60.5)                       | 2.03 (1.29–3.21)                | 2.27 (1.22–4.23) |
| 120 (56.1)                             | 84 (70.6)                       | 1.81 (1.12–2.90)                | 2.07 (1.05–4.09) |

**Secondary endpoints**

| \( \text{paO}_2 \leq 120 \text{ mmHg} \ N = 214 \) | \( \text{paO}_2 > 120 \text{ mmHg} \ N = 119 \) | Unadjusted OR value (CI 95%) | Adjusted OR value (CI 95%) |
|----------------------------------------|---------------------------------|------------------|------------------|
| 92 (43.0)                              | 72 (60.5)                       | 2.03 (1.29–3.21) | 2.27 (1.22–4.23) |
| 120 (56.1)                             | 84 (70.6)                       | 1.81 (1.12–2.90) | 2.07 (1.05–4.09) |

This table value of quantitative variables expressed as median and interquartile range. Values of qualitative variables expressed as \( n \) (%).

* Final model, adjusted for sex, age, APACHE, NIHSS, mismatch, reperfusion level achieved and orotracheal intubation at ICU admission

b NIHSS score obtained at 24 h after IAMT

---

**Fig. 3** Discriminative capacity of the model. ROC curve
Vasoconstriction may be related to hyperoxia-induced hypocapnia and not so much related to high oxygen levels [31].

In our series of more than 300 patients, we found an association between admission PaO2 > 120 mmHg and worse functional outcome 90 days after ischemic stroke. Thus, hyperoxia is twice as frequent in patients with mRS ≥ 4 or mRS ≥ 3. This association needs further confirmation by other studies.

It seems necessary to avoid the harmful effects of hyperoxia, in particular for conditions in which an ischemia–reperfusion mechanism prevails, as in the case of stroke [21, 32]. Hyperoxia levels are not well established yet. Thus, and observing our results, it would be prudent to avoid unnecessary administration of FiO2 that raises paO2 levels above the normal range.

This study has several limitations. Thus, being a multidisciplinary team with several services involved, supplemental oxygen until the start of thrombectomy was heterogeneous, especially during pre-hospital care. In addition, it was a prospective study with follow-up without repeated measures, with a single ICU admission blood gas analysis, so it was impossible to know exactly how long the hyperoxia conditions were maintained, since the FiO2 provided during the IAT was arbitrary.

In our series, the thrombectomy procedure was always performed under general anesthesia with intubation. This is a controversial issue, and, in many hospitals, it is performed with the patient awake, in spontaneous breathing. This decision was made in response to the requirements of the Neuroradiology Service to perform all the intra-arterial mechanical thrombectomies in our hospital. We consider that this homogenizes our cohort in terms of the respiratory support administered during the procedure. Perhaps, the results of our study should be applied only in that population of patients to whom IAT is performed under general sedoanalgesia, intubation and connection to mechanical ventilation.

Despite its limitations, our study shows that, in patients with ischemic stroke undergoing reperfusion therapy, hyperoxia is a variable independently associated with poor functional recovery. This hypothesis should be tested in additional prospective trials.

**Conclusions**

There is an association between high oxygen levels in the blood of patients that have suffered ischemic stroke after IAT and a worse functional outcome established by mRS of 3 scores or more and therefore with a higher degree of dependency.

Based on these results, we cannot assure that hyperoxia worsens the recovery of stroke patients, but it certainly constitutes an independent variable associated with a

| Lesion location | pO2 ≤ 120 mmHg N = 207 | pO2 > 120 mmHg N = 115 | Significance level (p value) |
|-----------------|------------------------|------------------------|-----------------------------|
| A1<sup>a</sup>  | 10 (4.7)               | 7 (5.9)                | 0.63                        |
| M1<sup>b</sup>  | 125 (58.4)             | 49 (41.2)              | <0.01                       |
| ICA<sup>c</sup>| 22 (10.3)              | 17 (14.3)              | 0.28                        |
| ICA + M1 (tandem lesions) | 50 (23.4) | 42 (35.3) | 0.02               |

This table value of qualitative variables expressed as n (%)

<sup>a</sup> Anterior cerebral artery, A1 segment
<sup>b</sup> Middle cerebral artery, M1 segment
<sup>c</sup> Internal carotid artery

| Primary endpoint | paO2 ≤ 120 mmHg N = 125 | paO2 > 120 mmHg N = 49 | Unadjusted OR value (CI 95%) | Adjusted OR value (CI 95%) |
|------------------|--------------------------|------------------------|-----------------------------|---------------------------|
| M1 group         |                          |                        |                             |                           |
| mRS ≥ 4 at 90 days | 44 (35.2)               | 30 (61.2)              | 2.91 (1.47–5.75)            | 2.81 (1.12–7.02)           |
| mRS ≥ 3 at 90 days | 62 (49.6)               | 35 (71.4)              | 2.54 (1.25–5.18)            | 3.56 (1.29–9.84)           |

This table value of quantitative variables expressed as median and interquartile range. Values of qualitative variables expressed as n (%)

<sup>a</sup> Final model, adjusted for sex, age, APACHE, NIHSS, GCS and preprocedure mismatch, wake-up stroke, time onset of symptoms to IAT and orotracheal intubation at ICU admission
poor functional recovery. A prospective, randomized study is needed to confirm these results.

Until there is enough evidence that supports routine oxygen supplementation in all stroke patients, we think that its use should be restricted to maintaining oxygen saturation within normal ranges. The purpose of this is to obtain a PaO2 level that ensures adequate tissue perfusion. It only seems prudent to avoid high-dose oxygen supplementation that might lead to a state of hyperoxia.

New clinical studies are necessary in order to assess more conservative strategies of oxygen therapy, especially in critical patients with conditions in which there is ischemia–reperfusion, like in the case of stroke.

Additional files

Additional file 1. Appendix that describes in detail the treatment algorithm, the inclusion and exclusion criteria and the anesthetic protocol during intra-arterial thrombectomy.

Additional file 2. Appendix that describes in detail the construction of the regression model.

Acknowledgements

The authors gratefully acknowledge Miguel Fernández for his assistance in the preparation of the manuscript. The Biomedical Research Institute of Murcia (IMIB) is acknowledged for the statistical review of the study.

Authors’ contributions

HLV, MFV and RNR designed the study. HLV, MFV, RNR, LAL and AMO contributed to the recruitment of patients and wrote the protocol. BGVM and AMD contributed to the completion of most thrombectomies. HLV, MFV, RNR, MGV and CLL collected the data. HLV, MFV, JRM and RNR analyzed and interpreted the data. HLV wrote and the manuscript. All authors read and approved the final manuscript.

Funding

No funding has been received from external companies for the preparation of this study.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved by Virgen de la Arrixaca Clinical University Hospital Ethical Committee for Clinical Research (License Number: Registry 02/17), and since there was no interference with patients’ management, signed informed consent was waived.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Intensive Care, Virgen de la Arrixaca, Clinical University Hospital, Murcia, Spain. 2 Department of Neuroradiology, Virgen de la Arrixaca, Clinical University Hospital, Murcia, Spain. 3 Department of Neurology, Biomedical Research Institute of Murcia (IMIB), Virgen de la Arrixaca, Clinical University Hospital, Murcia, Spain.

Received: 18 January 2019 Accepted: 15 May 2019

Published online: 24 May 2019

References

1. Organisation WH, WHO: stroke. cerebrovascular accident. Stroke 2011; health topics: stroke http://www.who.int/topics/cerebrovascular_accident/en/index.html.

2. Díaz-Guzmán J, Egido JA, Gabriel-Sánchez R, et al. Stroke and transient ischemic attack incidence rate in Spain: the IBERICTUS study. Cerebrovasc Dis. 2012;34:272–81.

3. Rowat AM, Dennis MS, Wardlaw JM. Hypoxemia in acute stroke is frequent and worsens outcome. Cerebrovasc Dis. 2006;21:166–72.

4. Berkhemer OA, Fransen PSS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11–20.

5. Campbell BCV, Mitchell PJ, Kleing J, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009–18.

6. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019–30.

7. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke. N Engl J Med. 2015;372:1009–18.

8. Cornell AD, Kooter AJ, Peters MJL, et al. Supplemental oxygen therapy in medical emergencies: more harm than benefit? Arch Intern Med. 2012;172:289–90.

9. Ray PD, Huang B, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012;24:981–90.

10. Allen CL, Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischemic stroke. Int J Stroke. 2009;4:461–70.

11. Cornet AD, Kooter AJ, Peters MJ, et al. The potential harm of oxygen therapy in medical emergencies. Crit Care. 2013;17:313.

12. Singhal AB. Oxygen therapy in stroke: past, present, and future. Int J Stroke. 2009;4:461–70.

13. de Jonge E, Peelen L, Keijzers PJ, et al. Association between administered oxygen, arterial partial oxygen pressure and mortality in mechanically ventilated intensive care unit patients. Crit Care. 2008;12:R156.

14. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138:923–36.

15. Ronning OM, Guldvog B. Should stroke victims routinely receive supplemental oxygen? A quasi-randomized controlled trial. Stroke. 1999;30:2033–7.

16. Chiu EHH, Liu C-S, Tan T-Y, et al. Venturi mask adjuvant oxygen therapy in severe acute ischemic stroke. Arch Neurol. 2006;63:741–4.

17. Singhal AB, Henneicke MG, Schneider D, von Reutern GM, Normobaric oxygen therapy in acute ischemic stroke trial—full text view—Clinicaltrial s.gov. https://clinicaltrials.gov/ct2/show/NCT00414726.

18. Rincon F, Kang J, Maltenfort M, et al. Association between hyperoxia and mortality after stroke. Crit Care Med. 2014;42:387–96.

19. Roffe C, Nevatte T, Sim J, et al. Effect of routine low-dose oxygen supplementation on death and disability in adults with acute stroke the stroke oxygen study randomized clinical trial. JAMA. 2017;318:1125–35.

20. Lee PJ, Choi AMK. Pathways of cell signaling in hyperoxia. Free Radic Biol Med. 2003;35:341–50.

21. Altemeier WA, Chin A. Hyperoxia in the intensive care unit: why more is not always better.Curr Opin Crit Care. 2007;13:73–8.

22. Wang C-H, Chang W-T, Huang C-H, et al. The effect of hyperoxia on survival following adult cardiac arrest: a systematic review and meta-analysis of observational studies. Resuscitation. 2014;85:1142–8.

23. Farquhar H, Weatherall M, Wjesinghe M, et al. Systematic review of studies of the effect of hyperoxia on coronary blood flow. Am Hear J. 2009;158:371–7.
24. Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37:1101–6.

25. Bulte DP, Chiarelli PA, Wise RG, et al. Cerebral perfusion response to hyperoxia. J Cereb Blood Flow Metab. 2007;27:69–75.

26. Johnston AJ, Steiner LA, Gupta AK, et al. Cerebral oxygen vasoreactivity and cerebral tissue oxygen reactivity. Br J Anaesth. 2003;90:774–86.

27. Floyd TF, Clark JM, Gelfand R, et al. Independent cerebral vasoconstrictive effects of hyperoxia and accompanying arterial hypocapnia at 1 ATA. J Appl Physiol. 2003;95:2453–61.

28. Rousseau A, Tesselaar E, Henricson J, et al. Prostaglandins and radical oxygen species are involved in microvascular effects of hyperoxia. J Vasc Res. 2010;47:441–50.

29. Zhilyaev SY, Moskvin AN, Platonova TF, et al. Hyperoxic vasoconstriction in the brain is mediated by inactivation of nitric oxide by superoxide anions. Neurosci Behav Physiol. 2003;33:783–7.

30. Ellsworth ML, Forrester T, Ellis CG, et al. The erythrocyte as a regulator of vascular tone. Am J Physiol. 1995;269:H2155–61.

31. Iscoe S, Fisher JA. Hyperoxia-induced hypocapnia: an underappreciated risk. Chest. 2005;128:430–3.

32. Suzuki S, Eastwood GM, Glassford NJ, et al. Conservative oxygen therapy in mechanically ventilated patients. Crit Care Med. 2014;42:1414–22.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.